Lepu Biopharma Co., Ltd. (2157.HK) HKSE

6.44

-0.03(-0.46%)

Updated at October 20 09:43AM

Currency In HKD

Lepu Biopharma Co., Ltd.

Address

Building 41

Shanghai, 201612

China

Phone

86 21 6769 6099

Sector

Healthcare

Industry

Biotechnology

Employees

498

First IPO Date

February 23, 2022

Key Executives

NameTitlePayYear Born
Dr. Ziye Sui M.D., Ph.D.Chief Executive Officer & Director2.68M1981
Ms. Lixuan ZhaoSupervisor & Investor Relations Director01992
Ms. Siu Kuen Lai FCIS, FCSJoint Company Secretary01976
Dr. Zhongjie PuExecutive Chairman01963
Ms. Yunyi LiChief Financial Officer & Board Secretary01980

Description

Lepu Biopharma Co., Ltd., a biopharmaceutical company, focuses on developing oncology therapeutics with a pipeline designed with a range of oncology products in China. The company develops oncology drug candidates, including antibody-drug conjugates (ADC), oncolytic virus drugs, and immunotherapies. It develops immuno-oncology products, such as HX008 Anti-PD-1 mAb and LP002 Anti-PD-L1 mAb; ADC products, including MRG003 EGFR-targeted ADC, MRG002 HER2-targeted ADC, MRG001 CD20-targeted ADC, MRG004A TF-targeted ADC, and CMG901 CLDNI8.2-targeted ADC; CG0070 oncolytic virus; and other drug candidates, such as HX008+OH2, LP002+OH2, and HX008+LP002. The company was incorporated in 2018 and is headquartered in Shanghai, China.